Performance status-1 - Slightly symptomatic Posts on Medivizor
Navigation Menu

Performance status-1 – Slightly symptomatic Posts on Medivizor

Looking for patients with metastatic triple-negative breast cancer to trial experimental vaccine with biological therapy

Posted by on Sep 20, 2019 in Breast cancer | 0 comments

In a nutshell This trial is examining the most beneficial dose of an experimental AE37 vaccine when used with biological therapy pembrolizumab (Keytruda). The main outcomes to be measured are the maximum safest dose of AE37 and objective response rate. This study is recruiting in Illinois and West Virginia, US. The details Triple-negative...

Read More

Looking for patients with advanced colorectal cancer to test an experimental treatment

Posted by on Sep 10, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the effectiveness of treatment with GB1275 alone or in combination with immunotherapy in patients with advanced solid tumors such as colorectal cancer. The main outcome to be measured will be dose toxicity and tumor response to the treatment. This study is being conducted in Tennessee and Texas, US. The...

Read More

Looking for patients with advanced triple negative breast cancer to test a new treatment

Posted by on Sep 10, 2019 in Breast cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the effectiveness of treatment with GB1275 alone or in combination with immunotherapy in patients with solid tumors such as triple-negative breast cancer. The main outcome to be measured will be dose toxicity and tumor response to the treatment. This study is being conducted in Tennessee and Texas, US. The...

Read More

Looking for patients with BRAF positive inoperable colorectal cancer to test a new treatment combination

Posted by on Aug 14, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the best dose and side effects of a combined treatment with encorafenib (Braftovi), cetuximab (Erbitux) and nivolumab (Opdivo). The main outcome to be measured will be the tumor response to the treatment. This trial is being conducted in Texas, US. The details Colorectal cancer is one of the leading...

Read More

Looking for patients with relapsed multiple myeloma to test a biological drug and immune cell vaccine

Posted by on Jul 31, 2019 in Multiple Myeloma | 0 comments

In a nutshell This trial is investigating the effectiveness and side effects of nivolumab (Opdivo) with a dendritic cell vaccine for patients with multiple myeloma (MM). The main outcome of this study would be to see the number of patients that develop an allergic reaction to the treatment. This study is recruiting in Boston, MA, United...

Read More

Looking for participants with advanced colorectal cancer to test a new combined treatment

Posted by on Jul 24, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the effectiveness of liposomal irinotecan (LI; Onivyde) and rucaparib (Rubraca) in treating patients with advanced colorectal cancer. The main outcome to be measured will be the toxicity and tumor response to the treatment. This trial is being conducted in Arizona, Georgia, Minnesota, and Utah, US. The...

Read More

Looking for participants with advanced cancer to test a new therapy

Posted by on Jul 24, 2019 in Colorectal cancer | 0 comments

In a nutshell This trial is examining the effectiveness and toxicity of COTI-2 treatment in patients with advanced cancer. The main outcomes to be measured will be cancer response to the treatment and number of side effects. This study is being conducted in Texas, US. The details Cancer resistance to therapy affects successful cancer treatment. The...

Read More

Looking for patients with breast cancer to trial a new chemotherapy drug combined with targeted therapy

Posted by on Jul 24, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 trial will investigate the effects of tesetaxel combined with targeted therapy drugs in advanced breast cancer (BC).  The main outcomes will be the overall response rate (ORR) and progression-free survival (PFS). This trial is recruiting in Boston, MA and East Setauket, NY.   The details Some...

Read More